Endocrine Abstracts

Objective: To assess metabolic control, cardiovascular risk factors and treatments in type 2 diabetes mellitus (T2DM) patients.

Methods: Observational and cross-sectional study of 238 T2DM patients who visited endocrinology clinics for the first time or those who did not undergo periodic revisions during the previous year of the study. All reported patients were outpatients, over 18 years of age and they signed informed consent statistical analysis was done by SPSS 20.0.

Results: 61.8% males; main age. 64.2±12.7 years. Diabetes duration (years): <1 8.8%; 1–5 20.2%; 5–10 25.2%; >10 45.8%. Cardiovascular risk factors: hypertension 80.7%, dyslipidaemia 80.3%, smoking 18.9% and obesity 61.4% (BMI 33.4±8.2 kg/m²).

30.3 and 24.7% of the patients have not HbA1c and lipids tests respectively during the 6 previous months. Hypoglycaemic agents: patients with and without treatment: 91.6 and 8.4% respectively. Oral therapy 58.6%; oral theraphy+insulin 21.2%; insulin 12.2%. Antihypertensive drugs 74.8%; lipid lowering drugs 64.3%; antiplatelet agents 41.1%.

Conclusion: The prevalence of risk factors was very high in our study. However, no patients achieved all ADA targets, in spite of the wide use of antihypertensive, lipid lowering and hypoglycaemic drugs.